4-[2-(5-bromo-2-chloro-pyridin-4-yl)-1-hydroxy-1-methyl-ethyl]-piperidine-1-carboxylic acid tert-butyl ester | 1382137-21-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[2-(5-bromo-2-chloro-pyridin-4-yl)-1-hydroxy-1-methyl-ethyl]-piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: 4-[2-(5-bromo-2-chloro-pyridin-4-yl)-1-hydroxy-1-methyl-ethyl]piperidine-1-carboxylic acid tert-butyl ester；4-[2-(5-bromo-2-chloropyridin-4-yl)-1-hydroxy-1-methylethyl]piperidine-1-carboxylic acid tert-butyl ester；4-[2-(5-bromo-2-chloro-pyridin-4-yl)-1-hydroxy-1-methylethyl]-piperidine-1-carboxylic acid tert-butyl ester；4-[2-(5-bromo-2-chloropyridin-4-yl)-1-hydroxy-1-methylethyl]-piperidine-1-carboxylic acid tert-butyl ester；4-[2-(5-Bromo-2-chloro-pyridin-4-yl)-1-hydroxy-1-methyl-ethyl]-piperidine-1-carboxylic acid tert-butyl ester；tert-butyl 4-[1-(5-bromo-2-chloropyridin-4-yl)-2-hydroxypropan-2-yl]piperidine-1-carboxylate
• CAS: 1382137-21-4
• 化学式: C₁₈H₂₆BrClN₂O₃
• 分子量: 433.773
• InChiKey: OYXLEKDKVMXBDR-UHFFFAOYSA-N

物化性质

• 沸点：
  503.9±45.0 °C(Predicted)
• 密度：
  1.381±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  62.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-Boc-4-哌啶甲酸乙酯 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 3.0h， 生成 4-[2-(5-bromo-2-chloro-pyridin-4-yl)-1-hydroxy-1-methyl-ethyl]-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  New compounds, pharmaceutical compositions and uses thereof

  摘要：

  本发明涉及一般式I的化合物， 其中基团R 1 ，L P ，L Q ，X 1 ，X 2 ，X 3 ，A，n和m如申请中所定义。公式I的化合物具有有价值的药理特性，特别是结合到GPR119受体并调节其活性。

  公开号：

  US20130018030A1

文献信息

• [EN] FUSED DIHYDROFURANS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY AND RELATED DISORDERS<br/>[FR] DIHYDROFURANES CONDENSÉS EN TANT QUE MODULATEURS DE GPR119 POUR LE TRAITEMENT DU DIABÈTE, DE L'OBÉSITÉ ET DE TROUBLES ASSOCIÉS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012098217A1

  公开（公告）日：2012-07-26

  The present invention relates to compounds of general formula (I), wherein the groups R1, LP, LQ, X1, X2, X3, A, n and m are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

  本发明涉及一般式(I)的化合物，其中基团R1、LP、LQ、X1、X2、X3、A、n和m如申请中所定义，具有有价值的药理特性，特别是结合到GPR119受体并调节其活性。
• NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20130150401A1

  公开（公告）日：2013-06-13

  The present invention relates to compounds of formula I, wherein R 1 , L P , L Q , X, A, and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

  本发明涉及公式I的化合物， 其中R 1 ，LP，LQ，X，A和n如申请中所定义，具有有价值的药理特性，特别是结合GPR119受体并调节其活性。
• 2,3-DIHYDROFURO[2,3-c]PYRIDIN-2-YLPIPERIDINE DERIVATIVES
  申请人：HIMMELSBACH Frank

  公开号：US20130331410A1

  公开（公告）日：2013-12-12

  The present invention relates to compounds of general formula I, wherein the groups R 1 , L Q and Ar are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

  本发明涉及一般式I的化合物， 其中基团R 1 ，L Q 和Ar如申请中所定义，具有有价值的药理特性，特别是结合GPR119受体并调节其活性。
• [EN] FUSED DIHYDROPYRANS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY AND RELATED DISEASES<br/>[FR] DIHYDROPYRANNES FONDUS UTILISÉS COMME MODULATEURS DE GPR119 POUR TRAITER LE DIABÈTE, L'OBÉSITÉ ET LES MALADIES ASSOCIÉES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012080476A1

  公开（公告）日：2012-06-21

  The present invention relates to compounds of general formula (I), wherein the groups R1, LP, LQ, X1, X2, X3, Ar and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

  本发明涉及一般式（I）的化合物，其中基团R1、LP、LQ、X1、X2、X3、Ar和n如申请中所定义，具有有价值的药理特性，特别是结合到GPR119受体并调节其活性。
• Compounds, pharmaceutical compositions and uses thereof
  申请人：HIMMELSBACH Frank

  公开号：US20120322784A1

  公开（公告）日：2012-12-20

  The present invention relates to compounds of formula I, wherein the groups R 1 , L P , L Q , X 1 , X 2 , X 3 , Ar and n are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.

  本发明涉及公式I的化合物， 其中R 1 ，LP，LQ，X 1 ，X 2 ，X 3 ，Ar和n的定义如申请中所述，具有有价值的药理特性，特别是结合GPR119受体并调节其活性。